Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 1:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 6,769 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Nerve Disorders Clear all
Completed Phase 1 Interventional

Indocyanine Green (ICG) Guided Tumor Resection

NCT04084067
View directory record Official record
Conditions
Neoplastic Disease, Solid Tumor
Interventions
Indocyanine Green
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Not listed
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 27, 2026, 1:51 AM EDT
Completed Phase 1Phase 2 Interventional

A Study of ADH-1 in Combination With Normothermic Isolated Limb Infusion of Melphalan

NCT00421811
View directory record Official record
Conditions
Neoplasms
Interventions
ADH-1, melphalan
Drug
Lead sponsor
Adherex Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
7
States / cities
Aurora, Colorado • Gainesville, Florida • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2010 · Synced Oct 27, 2026, 1:51 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Dynamic Light Scattering Ocular Measurement in the Detection of Dementia

NCT06613971
View directory record Official record
Conditions
Dementia, Dementia Alzheimer Type
Interventions
Not listed
Lead sponsor
MD Stem Cells
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Coconut Creek, Florida
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced Oct 27, 2026, 1:51 AM EDT
Completed Phase 2 Interventional

APX005M and Doxorubicin in Advanced Sarcoma

NCT03719430
View directory record Official record
Conditions
Soft Tissue Sarcoma
Interventions
Doxorubicin, APX005M
Drug
Lead sponsor
Alexander Z. Wei, MD
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
3
States / cities
Duarte, California • St Louis, Missouri • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 27, 2026, 1:51 AM EDT
Active, not recruiting Early Phase 1 Interventional

Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients

NCT02933736
View directory record Official record
Conditions
Glioblastoma Multiforme, Meningioma
Interventions
Ribociclib
Drug
Lead sponsor
Nader Sanai
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 27, 2026, 1:51 AM EDT
Terminated No phase listed Observational

Freehand Ultrasound Elasticity Imaging in Liver Surgery

NCT00942383
View directory record Official record
Conditions
Liver Tumors
Interventions
Not listed
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 28, 2019 · Synced Oct 27, 2026, 1:51 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Spectacles Lens in Concussed Kids

NCT03123822
View directory record Official record
Conditions
Concussion, Mild, Convergence Insufficiency, Accommodation; Insufficiency
Interventions
Glasses
Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
9 Years to 17 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 23, 2022 · Synced Oct 27, 2026, 1:51 AM EDT
Completed Not applicable Interventional Results available

Clinical Efficacy and Human Factors Validation Testing of the Erchonia EVRL for Providing Temporary Relief of Diabetic Peripheral Neuropathy Foot Pain

NCT05291975
View directory record Official record
Conditions
Neuropathy, Diabetic, Neuropathy;Peripheral, Neuropathy, Painful
Interventions
Erchonia® EVRL™, Placebo Laser
Device
Lead sponsor
Erchonia Corporation
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
4
States / cities
Phoenix, Arizona • West Covina, California • Dunedin, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2025 · Synced Oct 27, 2026, 1:51 AM EDT
Active, not recruiting Phase 2 Interventional

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

NCT03228667
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma, Head and Neck Squamous Cell Carcinoma, Merkel Cell Carcinoma, Melanoma, Renal Cell Carcinoma, Gastric Cancer, Cervical Cancer, Hepatocellular Carcinoma, Microsatellite Instability, Mismatch Repair Deficiency, Colorectal Cancer
Interventions
N-803 + Pembrolizumab, N-803 + Nivolumab, N-803 + Atezolizumab, N-803 + Avelumab, N-803 + Durvalumab, N-803 + Pembrolizumab + PD-L1 t-haNK, N-803 + Nivolumab + PD-L1 t-haNK, N-803 + Atezolizumab + PD-L1 t-haNK, N-803 + Avelumab + PD-L1 t-haNK, N-803 + Durvalumab + PD-L1 t-haNK, N-803 + Docetaxel + Pembrolizumab, N-803 + Docetaxel + Nivolumab
Drug
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
35
States / cities
Anchorage, Alaska • Hot Springs, Arkansas • El Segundo, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 27, 2026, 1:51 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic Melanoma or NSCLC

NCT02407171
View directory record Official record
Conditions
Melanoma, Lung Cancer
Interventions
MK-3475, Stereotactic Body Radiation Therapy (SBRT)
Drug · Radiation
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 31, 2023 · Synced Oct 27, 2026, 1:51 AM EDT
Completed Phase 1 Interventional

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors

NCT04242199
View directory record Official record
Conditions
Advanced Solid Tumor, MSI-H/dMMR Tumors, Cutaneous Squamous Cell Carcinoma, Urothelial Carcinoma, Cervical Cancer, HepatoCellular Carcinoma, Esophageal Squamous Cell Carcinoma, Merkel Cell Carcinoma, Small-cell Lung Cancer, Mesothelioma, PD-L1 Amplified Tumor (9p24.1), Nasopharyngeal Carcinoma
Interventions
INCB099280
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
5
States / cities
Boston, Massachusetts • Detroit, Michigan • Pittsburgh, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Oct 27, 2026, 1:51 AM EDT
Completed Not applicable Interventional Results available

Fecal Incontinence Treatment (FIT) Study

NCT03811821
View directory record Official record
Conditions
Fecal Incontinence, Bowel Incontinence
Interventions
Biofeedback, Injection
Behavioral · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
6
States / cities
Birmingham, Alabama • Augusta, Georgia • Ann Arbor, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 27, 2026, 1:51 AM EDT
Not listed Phase 1Phase 2 Interventional

Carmustine Followed By Surgery in Treating Patients With Recurrent Supratentorial Malignant Glioma or Metastatic Brain Neoplasm

NCT00009854
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Metastatic Cancer
Interventions
carmustine in ethanol, conventional surgery
Drug · Procedure
Lead sponsor
Direct Therapeutics
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
2
States / cities
San Francisco, California • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 6, 2013 · Synced Oct 27, 2026, 1:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Feasibility of Parasacral Transcutaneous Electrical Nerve Stimulation PTENS for Voiding Dysfunction in Peds Population

NCT04570605
View directory record Official record
Conditions
Overactive Bladder, Voiding Disorders, Incontinence, Urinary
Interventions
parasacral transcutaneous electrical nerve stimulation (PTENS), Standard Urotherapy
Device · Other
Lead sponsor
University of Utah
Other
Eligibility
6 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 17, 2022 · Synced Oct 27, 2026, 1:51 AM EDT
Completed Phase 2 Interventional Results available

Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors

NCT00088595
View directory record Official record
Conditions
Carcinoid Tumors
Interventions
Pasireotide (SOM230)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
4
States / cities
Los Angeles, California • Tampa, Florida • Iowa City, Iowa + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2012 · Synced Oct 27, 2026, 1:51 AM EDT
Completed Phase 2 Interventional Results available

Dendritic Cell Vaccines + Dasatinib for Metastatic Melanoma

NCT01876212
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
DC vaccine, Dasatinib
Biological · Drug
Lead sponsor
Walter J. Storkus
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 22, 2019 · Synced Oct 27, 2026, 1:51 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of an Antibiotic Sponge in Diabetic Patients With a Mild Infection of a Foot Ulcer

NCT00593567
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
gentamicin-collagen sponge, Levofloxacin
Drug
Lead sponsor
Innocoll
Industry
Eligibility
18 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Pasadena, Maryland
Source: ClinicalTrials.gov public record
Updated May 31, 2022 · Synced Oct 27, 2026, 1:51 AM EDT
Terminated Phase 2 Interventional Results available

Phase II Study of SOM230 in Patients With Recurrent or Progressive Meningioma

NCT00813592
View directory record Official record
Conditions
Cancer
Interventions
SOM230B
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 11, 2014 · Synced Oct 27, 2026, 1:51 AM EDT
Active, not recruiting Phase 4 Interventional

Evaluation of Trigeminal Nerve Blockade

NCT03632044
View directory record Official record
Conditions
Mouth Abnormalities, Cleft Palate, Birth Defect
Interventions
Ropivacaine, Sham Comparator
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
3 Months to 5 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 27, 2026, 1:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Neurobiology and Treatment of Reading Disability in NF-1

NCT00624234
View directory record Official record
Conditions
Neurofibromatosis Type 1, Reading Disabilities
Interventions
Tutoring Program I, Tutoring Program II
Behavioral
Lead sponsor
Vanderbilt University
Other
Eligibility
8 Years to 17 Years
Enrollment
184 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 8, 2025 · Synced Oct 27, 2026, 1:51 AM EDT
Recruiting Phase 2 Interventional

Nodal Radiation Therapy for Sentinel Lymph Node Positive Melanoma

NCT04594187
View directory record Official record
Conditions
Melanoma
Interventions
Immunotherapy, Quality-of-Life Assessment, Radiation Therapy
Other · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
3
States / cities
Jacksonville, Florida • Camden, New Jersey • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 27, 2026, 1:51 AM EDT
Recruiting No phase listed Observational

Determining Whether Multiple Anesthesia Exposures Affect Cognitive Function for Retinoblastoma Patients

NCT03546387
View directory record Official record
Conditions
Pediatric Retinoblastoma, Retinoblastoma
Interventions
Wechsler Intelligence Scale for Children, Fifth Edition (WISC-V), California Verbal Learning Test, Children's Version, Beery Developmental Test of Visual Motor Integration, 6th edition, Grooved Pegboard Test, Behavior Assessment System for Children/Parent Report
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
6 Years to 17 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 27, 2026, 1:51 AM EDT
Enrolling by invitation Phase 2 Interventional Accepts healthy volunteers

Ultralow Dose PET Imaging of 18F-FDOPA

NCT07542158
View directory record Official record
Conditions
Heathy Volunteer, Parkinsonian Syndromes, Neuroendocrine (NE) Tumors, Gliomas
Interventions
18F-FDOPA
Drug
Lead sponsor
Akiva Mintz
Other
Eligibility
18 Years to 120 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
1
States / cities
Englewood, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 27, 2026, 1:51 AM EDT
Completed Phase 1 Interventional

Calcium and Magnesium Infusion for the Prevention of Taxane Induced Neuropathy

NCT01682499
View directory record Official record
Conditions
Paclitaxel-induced Neuropathy
Interventions
calcium gluconate and magnesium sulfate
Drug
Lead sponsor
Beth Israel Medical Center
Other
Eligibility
21 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 25, 2014 · Synced Oct 27, 2026, 1:51 AM EDT